Probing the N-5 region of the indoloquinoline alkaloid, cryptolepine for anticryptococcal activity

Bioorganic and Medicinal Chemistry

Volumn 7, Issue 2, 1999, Pages 343-349

  Ablordeppey, Seth Y ^a   Fan, Pingchen ^a   Clark, Alice M ^b   Nimrod, Alison ^b  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Anticryptococcal agents; Antifungal agents; Cryptolepine; Indoloquinolines; Opportunistic infections

Indexed keywords

AMPHOTERICIN B; CRYPTOLEPINE; CRYPTOLEPINE DERIVATIVE; INDOLOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CHEMICAL MODIFICATION; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

ALKALOIDS; ALKYLATION; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, CHEMICAL; QUINOLINES; TEMPERATURE;

EID: 0032977368     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(98)00244-2     Document Type: Article

References (32)

1. Polak, A. Prog. Drug. Res. 1997, 49, 219.
2. Georgiev, V. S. Med. Chem. Res. 1993, 13, 493.
3. Georgiev, V. S. Med. Chem. Res. 1993, 13, 507.
4. Bigger, R. J. Lancet 1986, I, 79.
5. Piot, P.; Taelman, H.; Minlangu, K. B.; Mbendi, N.; Ndangi, K.; Kalambai, K.; Bridts, C.; Quinn, T. C.; Feinsod, F. M.; Wobin, O.; Mazebo, P.; Stevens, W.; Mitchell, S.; McCormick, J. B. Lancet 1984, II, 65.
6. Bennett, J. E.; Dismuskes, W. E.; Duma, R. J.; Medoff, G.; Sande, M. A.; Gallis, H.; Leonard, J.; Fields, B. T.; Bradshaw, M.; Haywood, H.; McGee, Z. A.; Cate, T. R.; Cobbs, C. G.; Warner, J. F.; Alling, D. W. N. Eng. J. Med. 1979, 301, 127.
7. Dismuskes, W. E.; Cloud, G.; Gallis, H. A.; Kerkering T. M.; Medoff, G.; Craven, P. C.; Kaplowitz, L. G.; Fisher, J. F.; Gregg, C. R.; Bowles, C. A.; Shadomy, S.; Stamm, A. M.; Diasio, R. B.; Kaufman, L.; Soong, S. J.; Blackwelder, W. C. and National Institute of Allergy and Infections Diseases Mycoses Studying Group. N. Eng. J. Med. 1987, 317, 334.
8. Francis, P.; Walsh, T. J. Clin. Infect. Dis. 1992, 15, 1003.
9. Larsen, R. A.; Bozzette, S. A.; Jones, B. E.; Haghighat, D.; Leal, M. A.; Forthal, D.; Bauer,M.; Tilles, J. G.; McCutchan, J. A.; Leedom, J. M. T. J. Clin. Infect. Dis. 1994, 19, 741.
10. AHFS Drug Information; McEvoy, G. K., Ed.; American Society of Hospital Pharmacists: USA, 1997; pp 74-79.
11. Johnson, E. M.; Warnock, D. W.; Luker, J.; Porter, S. R.; Scully, C. J. Antimicrob. Chemother. 1995, 35, 209.
12. Rex, J. H.; Rinaldi, M. G.; Pfaller, M. A. Antimicrob. Agents Chemother. 1995, 39, 1.
13. Dwuma-Badu, D.; Ayim, J. S. K.; Fiagbe, N. I. Y.; Knapp, J. E.; Schiff, Jr., D. L.; Slatkin, D. J. J. Pharm. Sci. 1978, 67, 433.
14. Ablordeppey, S. Y.; Hufford, C. D.; Borne, R. F.; Dwuma-Badu, D. Planta Med. 1990, 56, 416.
15. Cimanga, K.; Bruyne, T. D.; Lasure, A.; Poel, B. V.; Pieters, L.; Claeys, M.; Berghe, D.-V.; Kambu, K.; Tona, L.; Vlietinck, A. J. Planta Med. 1996, 62, 22.
16. Repeated in vitro testing using agar well diffusion assay shows the zone of inhibition of cryptolepine to be 13 mm while that of Amphotericin B was 11 mm against C. neoformans. For a possible explanation for the reversal of activities in the agar well diffusion assay and the broth dilution assay see: Singh, M.; Singh, M. P.; Ablordeppey, S. Y. Drug. Dev. Ind. Pharm. 1996, 22, 377.
17. Boakye-Yiadom, K.; Herman Ackah, S. M. J. Pharm. Sci. 1979, 68, 1510.
18. Oyekan, A. O.; Ablordeppey, S. Y. Med. Chem. Res. 1996, 6, 602.
19. Ansa-Asamoah, R. Asante-Frempong, Preliminary studies on the short term toxicity of cryptolepine in mice, First International Conference on Cryptoleine; Boakye-Yiadom, K.; Bamgbose, S. O. A., Eds.; UST, Kumasi, Ghana, 1983, p 52.
20. Tremblay, C.; Barza, M.; Fiore, C.; Szoka, F. Antimicrob. Agents Chemother. 1984, 26, 170.
21. A crude estimate of the water solubility of cryptolepine HI salt was undertaken. Excess cryptolepine was mixed with 1 mL of water and shaken overnight. The mixture was then filtered and the filtrate was concentrated to obtain 1.2 mg of cryptolepine salt. The solubility of amphotericin B was obtained from: The Merck Index, Budavari, S., Ed; Merck & Co: NJ, 1996; Vol 12, p 99.
22. Holt, S. J.; Petrow, V. J. Chem. Soc. 1947, 607.
23. Cooper, M. M; Lovell, J. M.; Joule, J. A. Tetrahedron Lett. 1996, 37, 4283.
24. Gorlitzer, K; Weber, J. Arch. Pharm. (Weinheim) 1981, 314, 852.
25. Yamato, M.; Takeuchi, Y.; Chang, M.; Hashigaki, K. Chem. Pharm. Bull. 1992, 40, 528.
26. Takeuchi, Y.; Chang, M.; Hashigaki, K.; Tashiro, T.; Tsuruo, T.; Tsukagoshi, S.; Yamato, M. Chem. Pharm. Bull. 1992, 40, 1481.
27. Bierer, D. E.; Fort, D. M.; Mendez, C. D.; Luo, J.; Impach, P. A.; Dubenko, L. G.; Gerber, R. E.; Litvak, J.; Lu, Q.; Zhang, P.; Reed, M. J.; Waldeck, N.; Bruening, B.; Noamesi, K.; Hector, R. F.; Carlson, T. J.; King, S. R, J. Med. Chem., 1998, 41, 894.
28. Fan, P., Ablordeppey, S. Y.; J. Heterocyclic. Chem. 1997, 34, 1789.
29. Unpublished results.
30. Jenkins, C. L.; Kochi, J. K., II. J. Org. Chem. 1971, 36, 3103.
31. Chand, S.; Lusunzi, I.; Veal, D. A.; Williams, L. R., Karuso, P. J. Antibiotics 1994, 47, 1295.
32. The method of MCI determination in C. albicans and C. neoformans is an adaptation of standard methods (NCCLS, 1997). In the procedure, Sabaraud's dextrose broth (C. albicans) and mycophil broth (C. neoformans) were substituted for RPMI-1640 as growth media. Such substitution follows observations in our laboratories that antifungal alkaloids exhibit inconsistent MIC determinations when tested in RPMI-1640, National Committee for Clinical Laboratory Standards, 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA, USA.